Giovanni Amabile, PhD


Giovanni joined Enthera as COO in 2018 and was appointed CEO in December 2019.

Giovanni has demonstrated an ability to develop biologic therapeutics, with a successful track record of Marketing Authorization approvals in the US and Investigational New Drug approvals for monoclonal antibodies (mAbs). He also brings strong regulatory expertise in both the US and EU. Giovanni formerly served as Manager of Medical Affairs at Biogen Idec where he was responsible for translating scientific and medical information to the neurology community and promoting company-sponsored studies to support both pipeline and licensed products. More recently, Giovanni served as CSO at ADIENNE Pharma & Biotech SA where he supervised mAbs development and was responsible for several pre-clinical and clinical research programmes, as well as for the Group’s scientific and clinical strategy

Giovanni has more than 10 years of academic research experience from institutions such as the Whetherall Institute of Molecular Medicine and Harvard Medical School. With several key publications in the field of hematology and stem cells, he is recognized as an expert in the stem cell field.